Healthcare/ Market Access/ News/ News/ Pharma Market Access/ R&D Can Spark make a profit on its groundbreaking gene therapy? Andrew McConaghie cell and gene therapy, gene therapy, Luxturna, Rare diseases, Spark Therpeutics 0 Comment Spark Therapeutics is on the cusp of gaining the first ever approval for a gene therapy from the Share X Can Spark make a profit on its groundbreaking gene therapy? https://pharmaphorum.com/news/can-spark-make-profit-groundbreaking-gene-therapy/